

Stanford

Tami Denise John

Clinical Associate Professor, Pediatrics - Stem Cell Transplantation

CLINICAL OFFICE (PRIMARY)

- **LPCH Bass Center**

750 Welch Rd

Palo Alto, CA 94304

Tel (650) 725-9250 Fax (650) 723-5231

Bio

CLINICAL FOCUS

- Pediatric Hematology-Oncology

ACADEMIC APPOINTMENTS

- Clinical Associate Professor, Pediatrics - Stem Cell Transplantation

PROFESSIONAL EDUCATION

- Board Certification: Pediatric Hematology-Oncology, American Board of Pediatrics (2017)
- Fellowship: Texas Children's Hospital BMT Fellowship Program (2017) TX
- Fellowship: UC Irvine Pediatric Hematology/Oncology Program (2016) CA
- Board Certification: Pediatrics, American Board of Pediatrics (2013)
- Residency: UC Davis Dept of Pediatrics Residency Program (2013) CA
- Medical Education: Wake Forest University Office of the Registrar (2010) NC

Research & Scholarship

CLINICAL TRIALS

- Phase II/III Posoleucel vs Placebo in Prevention of Infection/Disease in HighRisk After AllogeneicHCT, Not Recruiting

Publications

PUBLICATIONS

- **Clinical Hematopoietic Stem Cell-Based Gene Therapy.** *Molecular therapy : the journal of the American Society of Gene Therapy*
John, T., Czechowicz, A.
2025
- **Incremental Eligibility Criteria for the BMT CTN 1507 Haploidentical Trial for Children with Sickle Cell Disease.** *Blood advances*
John, T. D., Walters, M. C., Rangarajan, H. G., Rahim, M. Q., McKinney, C. M., Bollard, C. M., Abusin, G., Eapen, M., Kassim, A. A., DeBaun, M. R.
2024
- **Dismantling cost and infrastructure barriers to equitable access to gene therapies for sickle cell disease.** *The Lancet. Haematology*
Sharma, A., John, T. D.
2024

- **Strategic infection prevention after genetically modified hematopoietic stem cell therapies: recommendations from the International Society for Cell & Gene Therapy Stem Cell Engineering Committee.** *Cytotherapy*
John, T. D., Maron, G., Abraham, A., Bertaina, A., Bhoopalan, S. V., Bidgoli, A., Bonfim, C., Coleman, Z., DeZern, A., Li, J., Louis, C., Oved, J., Pavel-Dinu, et al
2024
- **Red Cell Rheology and Blood Viscosity in Pediatric Individuals Having Received Allogenic Hematopoietic Stem Cell Transplantation or Ex Vivo Autologous Gene Therapy for Sickle Cell Disease**
Patel, A. P., Kanne, C. K., Stenger, E. O., John, T. D., Sheehan, V. A.
AMER SOC HEMATOLOGY.2023
- **Regimen Intensity and Age Affect Transplant-Related Outcomes after Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Registry Study**
John, T. D., Chellapandian, D., Shah, R., Gillespie, S., Liu, K., Xiang, Y., Bhatia, M., Chaudhury, S., Eckrich, M. J., Guilcher, G. M. T., Jaroscak, J., Kasow, K. A., Krajewski, et al
AMER SOC HEMATOLOGY.2023
- **Donor Hemoglobin Genotype Does Not Impact Outcomes Following Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Study**
Stenger, E., John, T. D., Chellapandian, D., Shah, R., Gillespie, S., Xiang, Y., Liu, K., Bhatia, M., Guilcher, G. M. T., Jaroscak, J., Kasow, K. A., Krajewski, J., Ngwube, et al
AMER SOC HEMATOLOGY.2023